Addex announces adx71149 phase 2 epilepsy clinical study's independent interim review committee recommends continuing study

Cohort 1 progressing through p art 2 cohort 2 recruiting patients ad hoc announcement pursuant to art. 53 lr geneva, switzerland, may 10 , 202 3 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the adx71149 (jnj-40411813) phase 2 epilepsy clinical study has been recommended to continue by an independent interim review committee (irc) following review of unblinded data from part 1 of patient cohort 1.
ADXN Ratings Summary
ADXN Quant Ranking